Sofiva Genomics Co.,Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 12, 2019 at 06:50 pm IST
Share
Sofiva Genomics Co.,Ltd. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced sales was TWD 130.368 million compared to TWD 112.340 million a year ago. Operating income was TWD 18.879 million compared to TWD 8.780 million a year ago. Net income was TWD 17.467 million compared to TWD 6.969 million a year ago. Basic earnings per share was TWD 0.83 compared to TWD 0.33 a year ago. Diluted earnings per share was TWD 0.82 compared to TWD 0.33 a year ago. For the nine months, sales was TWD 385.477 million compared to TWD 340.591 million a year ago. Operating income was TWD 53.338 million compared to TWD 41.677 million a year ago. Net income was TWD 50.660 million compared to TWD 36.976 million a year ago. Basic earnings per share was TWD 2.39 compared to TWD 1.77 a year ago. Diluted earnings per share was TWD 2.36 compared to TWD 1.74 a year ago.
Sofiva Genomics Co Ltd is a Taiwan-based company mainly engaged in provision of deoxyribonucleic acid (DNA) testing services. The Company's DNA testing services mainly contain reproductive medicine testing, pregnant women testing, newborn testing, rare disease genetic testing, personalized genetic testing, cancer genetic testing, and genetic counseling services. Reproductive Medicine testing is pre-implantation genetic diagnosis for embryos. Pregnant women testing services predict the occurrence of preeclampsia and provide prenatal diagnosis. Neonatal testing services provide neonatal hearing loss genetic test, respiratory distress syndrome test, congenital cytomegalovirus infection test service. Personalized genetic testing services includes human papilloma virus screening, paternity testing, telomere testing, chronic disease and cardiovascular disease and other genetic research. Cancer genetic testing services is applied to cancer patients.
SOFIVA GENOMICS CO.,LTD. 
